Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)

INTRODUCTION: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR activating tyrosine kinase domain mutations. Most data available pertain to Asian populations in which such mutations are mo...

Descripción completa

Detalles Bibliográficos
Autores principales: De Grève, Jacques, Van Meerbeeck, Jan, Vansteenkiste, Johan F., Decoster, Lore, Meert, Anne-Pascale, Vuylsteke, Peter, Focan, Christian, Canon, Jean-Luc, Humblet, Yves, Berchem, Guy, Colinet, Benoit, Galdermans, Danny, Bosquée, Lionel, Vermeij, Joanna, Dewaele, Alex, Geers, Caroline, Schallier, Denis, Teugels, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816447/
https://www.ncbi.nlm.nih.gov/pubmed/27032107
http://dx.doi.org/10.1371/journal.pone.0147599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816447/
https://www.ncbi.nlm.nih.gov/pubmed/27032107
http://dx.doi.org/10.1371/journal.pone.0147599

Ejemplares similares